Background Patients with lung cancer are at an increased risk for venous thromboembolism
(VTE). Approximately 8–15% of patients with advanced non-small-cell lung cancer (NSCLC) …

Lung cancer is the most commonly diagnosed cancer in Canada and remains associated
with high mortality. Nevertheless, recent advances in the fields of immuno-oncology and …

Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic
management has advanced with the identification of various key oncogenic mutations that …

Simple Summary The chemotherapy agent pemetrexed is currently considered in
combination with other therapies for the treatment of advanced nonsquamous non-small-cell …

Objectives No overall survival (OS) benefit has been reported from a mature randomized
trial with the use of ALK inhibitors. We conducted a systematic review and meta-analysis to …

Anaplastic lymphoma kinase (ALK) rearrangement, one of the common oncogene
rearrangements in the mutational history of lung adenocarcinoma, occurs in approximately …

Background: In patients with anaplastic lymphoma kinase (ALK) rearrangement-positive
advanced non–small-cell lung cancer (NSCLC), ALK inhibitors are now the standard …

The pathogenesis of lung cancer associated with idiopathic pulmonary fibrosis (IPF) has
remained largely uncharacterized. To provide insight into this condition, we undertook …

Lung cancer is generally treated with conventional therapies, including chemotherapy and
radiation. These methods, however, are not specific to cancer cells and instead attack every …

Purpose Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We
retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with …